

**Gap analysis workshop on Contagious Bovine Pleuropneumonia (CBPP),  
June 26th-28th, 2023, Wellcome-Sanger Institute, Hinxton, UK.**



**Immune responses associated with protection against  
CBPP and induced by immunization**

Philippe Totté  
CIRAD-UMR ASTRE  
« AnimalS health Territories Risks Ecosystems »






## The disease

- contagious bovine pleuropneumonia (CBPP)
- Africa
- lymphatics / lungs

Picture credit to F. Thiaucourt



Picture credit to F. Thiaucourt



- chronic CBPP
- sequestrum
- long term persistence
- and excretion ?

Picture credit to F. Thiaucourt



- acute CBPP (15-30%)
- massive inflammation of lungs
- hepatisation
- pleurisy

# Immune responses associated with protection against CBPP and induced by immunization


## Innate immunity

1/3


### Effect of complement in vitro

Totté P et al. 2023. *PCI microbiol.* <https://microbiol.peercommunityin.org/articles/rec?id=5>

→ Bactericidal capacity is highly variable between animals but conserved over time



-10%: ↓ 0-2 logs in CFU/ml  
 -20%: ↓ 1,5-3 logs in CFU/ml  
 No effect after  
 de complementation of sera



1h incubation in RPMI, 3 different cattle



→ No opsonization effect at non bactericidal concentrations

Serum = presence of complement

*Mmm*NeonGreen + macrophages (Mac) → uptake (flow cytometry)

*Mmm* + Mac → killing (CFU in cellular fraction)

Dashed line =  
 =  
*Mmm*+Mac




## Innate immunity

2/3

### ● Effect of bovine complement in vitro

- No pro-inflammatory effect on macrophages (TNF) at non bactericidal concentrations
- Reduces *Mmm*-induced TNF response of macrophages at bactericidal concentrations



- uninfected (Mmm-) or infected with Mmm (Mmm+) at an MOI of 500-1000
- absence (FCS) or presence of non-decomplemented bovine sera at non-bactericidal (serum1) and bactericidal (serum2)
- TNF titration by ELISA in 24h supernatants

# Immune responses associated with protection against CBPP and induced by immunization

## Innate immunity


- Effect of bovine complement in vitro

Totté P et al. 2023. PCI Microbiol



- Interactions between *Mmm* and bovine macrophages in vitro

- No killing in the absence of specific antiserum
- No intracellular survival (Gentamicin assay)
- No opsonizing effect of complement at non bactericidal concentrations
- Phagocytosis-independent uptake in the absence of specific antiserum

3/4



MOI = 500



- TNF production in response to *Mmm* (MOI 500)

## Innate immunity (discussion & perspectives)

4/4

### 1- Potential role of complement

- individual bactericidal effect of complement in vitro as a marker of resistance ?  
→ confirm in infection trials
- no impact on TNF response of macrophages at non bactericidal concentrations  
→ confirm in alveolar macrophages, effect on neutrophils?
- reduces TNF production by macrophages at bactericidal concentrations  
→ reduction of inflammation

### 2- Minor role of macrophages

- no killing in the absence of antiserum  
→ consistent with previous work on mycoplasmas using alveolar macrophages  
→ increased killing in the presence of IFN- $\gamma$  ?
- at MOI>500: phagocytosis-independent uptake is associated with TNF production  
→ confirm using alveolar macrophages  
→ autophagy? C-type lectin receptors ?

### 3- Role of neutrophils?


- neutrophil extracellular traps (NETs)

## Humoral immunity

1/4

### ● during primary infection (challenge by contact and intubation)

- No correlation between CFT (Bygrave *et al.*, 1968) and IgM+IgG/Elisa (Le Goff and Lefevre, 1989) responses and disease severity
- Antibody transfer experiments using serum from convalescent animals have been inconclusive (Gourlay *et al.*, 1979).
- Detection by ELISA of *Mmm*-specific IgA in serum and bronchoalveolar lavage (BAL) of animals with less severe disease (Niang M *et al.* Vet Res. 2006)



- detectable for only 1-3 months in serum




## Humoral immunity

- during primary infection (challenge by contact and intubation)

- during vaccination/immunization

- Weak antibody titers (CFT, cELISA, indirect ELISA) and most animals are negative after 3 months. No correlation with reduced disease after contact challenge (Thiaucourt F *et al.* Ann. N Y Acad Sci 2000)
- Strong IgG titers against 4 out of 65 recombinant surface proteins (Luminex bead array) in animals vaccinated with T1/44. LppQ as most prominent target of IgG (n=5)(Hamsten C *et al.* Clin Vaccine Immunol. 2010)



- IgG responses after challenge by contact for one animal representative of each group
- T1/44: only one animal with small sequestra after challenge
- recProt&Naive: 5/5 with small to large sequestra

- Animals immunised against LppQ are not protected against challenge and show increased glomerulonephritis (Mulongo *et al.*, 2015).

## Humoral immunity

- during primary infection (challenge by contact and intubation)
- during vaccination/immunization
- in vitro studies
  - A monoclonal IgM antibody directed against a carbohydrate epitope inhibits the growth of *Mmm* in vitro in the absence of phagocytes and complement, which is the basis for the growth inhibition diagnostic assay (Kiarie *et al.*, 1996).
  - 13/48 (10 IgG2, 2 IgG1, 1 IgM) anti-*Mmm* mouse Mabs induce 30 to 70% inhibition of *Mmm* adhesion to lung epithelial cells. One Mab (IgM) against galactane (capsule) is also bactericidal due to agglutination (Aye *et al.*, 2018)
  - Antiserum from convalescent animals induce killing of *Mmm* by bovine macrophages (Totté *et al.*, 2023)

## Humoral immunity (discussion&perspectives)

4/4

- No or poor correlation with milder symptoms except for IgA in broncho-alveolar lavage (BAL)
  - confirm results for IgA in larger animal group
  - repeat transfer experiments using improved nebulization-based challenge methods
  - more studies in BAL
- Suspicion about antibody-antigen immunocomplexes as inducers of vasculitis and nephritis
  - identify antigens and inactivate corresponding gene in vaccine strains
- Antibodies against capsular galactan that block adhesion and promote agglutination
  - only IgM ? → one study shows comparable protection levels between T1 and galactan vaccines (Mwirigi et al, 2016)
  - further explore potential of immunization against galactan
- Antibodies from convalescent animals promote phagocytosis-dependent killing of *Mmm* by macrophages
  - confirm with alveolar macrophages
  - identify target antigens

# Immune responses associated with protection against CBPP and induced by immunization (resistance to / recovery from)

## Cell mediated immunity (CMI)



1/4

### ● during primary infection (contact/intubation challenge)

→ Positive intradermal test 3 months after infection suggests the presence of CMI (Roberts et al., 1973)


→ Contradictory results with IFN- $\gamma$  responses in ex vivo stimulated pbmc cultures

1- Dedieu et al (2005): higher IFN- $\gamma$  in convalescent and fully recovered animals compared to animals with acute cbpp (hepatization, respiratory distress)



Challenge by contact: 6 animals  
- 3 with sequestra (convalescent)  
- 3 with scars (fully recovered)  
- 3 with hepatization + respiratory distress (acute) C

2- Jores et al (2008): no difference between animals with lesions and those without any lesions



Challenge by intubation: 15 animals  
- 5 without lesions (30%)  
- 6 with sequestra  
- 4 with hepatization (acute)

# Immune responses associated with protection against CBPP and induced by immunization (resistance to / recovery from)

2/4

## Cell mediated immunity (CMI)

### ● during primary infection (contact/intubation)

recall = *in vitro* restimulation  
With killed Mmm

→ Recall activation of CD4+ T cells in pbmc and draining lymph nodes of chronically infected and fully recovered animals (Dedieu *et al.*, 2003 and 2006)

- No proliferation/enrichment of CD4 detected in day5 cultures → immune tolerance ?


→ Recall proliferation (cfse) of B and CD4 under the control of T1 type CD4+ T cells in draining lymph nodes of chronically infected and fully recovered animals (Totté *et al.*, 2008)

- No proliferation and no IFN- $\gamma$  after depletion of CD4


- CD4 enrichment detected in day6 cultures → active and sustained proliferation

- ↑ expression of memory marker on CD4

- IFN- $\gamma$  produced by CD4 in the absence of IL-4 (elisa, intracellular staining) → T1 type



→ CD4 with effector memory (Tem: CD62L<sup>low</sup>, CCR7<sup>-</sup>, IFN- $\gamma$ <sup>+</sup>) and central memory (Tcm: CD62L<sup>hi</sup>, CCR7<sup>+</sup>, IFN- $\gamma$ <sup>+/-</sup>) are found in draining lymph nodes of chronically infected and fully recovered animals (Totté *et al.*, 2010)



→ Depletion studies suggest that CD4+T lymphocytes play a minor role during primary infection (Sacchini *et al.*, 2011)


## Cell mediated immunity (CMI)

- during primary infection (contact/intubation)
- during immunization (T1 vaccines)

*recall = in vitro restimulation  
With killed Mmm*

- ➔ No recall activation of lymphocytes in cattle vaccinated 2 months previously in the tail tip with a single dose of the T1 vaccine (Roberts DH, et al. Infect Immun 1973)
- ➔ *Mmm*-specific recall proliferation of CD4+Tem and Tcm but only after 3 shots of vaccine (n=5) and lower Tcm response in comparison to animals that recovered from CBPP (Totté *et al.* 2013)

recall responses (cfse+Facs) one month after vaccine injections (d9 cultures)



- same for IFN- $\gamma$  recall responses (Elisa,Elispot)


- ➔ No differential regulation of bovine genes (Agilent microarray) in pbmc collected 6 months after vaccination and restimulated 24h in vitro (Totté et al., final report of the Ben-1 project funded by Galvmed, 2017)

-weak recall proliferation in pbmc detected only 4 months after vaccination (Jorg et al., personal communication)

## Cell mediated immunity (CMI) (Discussion & perspectives)

4/4

- Strong memory responses (short- and long-term) under the control of CD4 in fully recovered animals
  - need to confirm protection in these animals. Is protection associated with chronic CBPP?
  - assess these responses in animals undergoing secondary challenge
  - further characterization of CD4 (Treg, Th17, Th22) in fully recovered animals
- Weak CD4 recall/memory responses are induced by T1/44 vaccine lessons from the bovine tuberculosis model (Bhujra S *et al.*, 2012)
  - increase using adjuvants promoting Th1 CMI
  - omic approach to define markers that can predict vaccine efficacy after vaccination but before challenge
- Analysis of CMI in animals undergoing secondary challenge
  - whole bovine genome transcriptomic approach to grasp complex acquired immunity
  - ex vivo stimulation of blood lymphocytes to analyze long-term Tcm memory responses (IFN- $\gamma$  cultured Elispot)
  - correlates of protective immune memory to help the design/selection of better vaccines





# Thanks to my colleagues at Cirad



## WOAH Reference Laboratory for CBPP at CIRAD, Montpellier, France

F. Thiaucourt  
L. Manso-Silvan  
A. Peyraud  
A. Boissière  
M. Durand  
L. Rousset



WOAH Reference Laboratory for CBPP



Reference Centre



World Organisation for Animal Health  
Founded as OIE

# And in Africa

LCV in Mali



ILRI and KALRO in Kenya



LANAVET in Cameroon



CVRI in Zambia





**Thank you for your attention**